See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Natural Disasters
Social Media
Soccer
Donald Trump
Floods
Trade War
Baseball
US Politics
Instagram
Premier League
Trade
Published • loading... • Updated

Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD

Summary by Gilbert Sun News
Primary endpoint met, with TSND-201 demonstrating statistically significant placebo-adjusted CAPS-5 improvement of -9.64 points on Day 64 (p = 0.011)TSND-201 demonstrated rapid improvements, with a statistically significant placebo-adjusted CAPS-5 improvement of -8.00 points on Day 10 (p = 0.012), with…

4 Articles

All
Left
Center
1
Right
Gilbert Sun NewsGilbert Sun News
Center

Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD

Primary endpoint met, with TSND-201 demonstrating statistically significant placebo-adjusted CAPS-5 improvement of -9.64 points on Day 64 (p = 0.011)TSND-201 demonstrated rapid improvements, with a statistically significant placebo-adjusted CAPS-5 improvement of -8.00 points on Day 10 (p = 0.012), with…

Read Full Article
psychedelicalpha.compsychedelicalpha.com

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program - Psychedelic Alpha

Words by Josh Hardman with support from Psychedelic Alpha Medical Advisor Michael Haichin. *** Today, Transcend Therapeutics shared topline results from its Phase 2 study of the MDMA analog methylone (TSND-201) in PTSD. The trial, IMPACT-1 (NCT05741710), enrolled 65 severe PTSD patients to receive either methylone or placebo capsules once weekly for four weeks… Source

Read Full Article
Clinical Trials ArenaClinical Trials Arena

Transcend’s PTSD therapy shows potential in Phase II trial

The company’s Phase II IMPACT-1 trial found treatment with TSND-201 was generally safe and well tolerated in PTSD patients.The post Transcend’s PTSD therapy shows potential in Phase II trial appeared first on Clinical Trials Arena.

Read Full Article
Endpoints NewsEndpoints News

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 trial that could begin at the start of next year. The placebo-controlled results ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal